CYP19A1 and breast cancer: In certain patients with HR-positive/HER2-negative breast cancer, clinical guidelines recommend endocrine therapy (aromatase inhibitor) in combination with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor as first-line treatment for advanced disease6–8.